Figure 6
From: The role of autophagy in allergic inflammation: a new target for severe asthma
The effect of dexamethasone and montelukast treatment on AHR, airway inflammation and LC3 expression. (A) Changes in lung resistance in response to increasing doses of methacholine were assessed 48 h after the final challenge. (B) Airway inflammatory cell counts in BALF. (C) Cytokine levels in BALF. (D) H&E-stained lung histology. (E) PAS-stained lung histology. (F) LC3 expression after dexamethasone and montelukast treatments. (a) PBS/2% OVA challenged mice. (b) OVA/2% OVA challenged mice. (c) Dexamethasone treatment in OVA/2% OVA-challenged mice. (d) Montelukast treatment in OVA/2% OVA-challenged mice. (e) Quantification of inflammatory cells or PAS-positive cells. The data are expressed as the mean±s.e.m. ##P<0.01 versus PBS/2% OVA, **P<0.01 versus OVA/2% OVA. AHR, airway hyperresponsivenessl; BALF, bronchoalveolar lavage fluid; Dex, dexamethasone; H&E, hematoxylin and eosin; Mon, montelukast; OVA, ovalbumin; PAS, periodic acid-Schiff; PBS, phosphate-buffered saline.
